Directed Differentiation of Pluripotent Stem Cells for Vascular Disease Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing endothelial cells and pericytes are inefficient and unsuitable for modeling vascular diseases like Hereditary Hemorrhagic Telangiectasia (HHT), as they fail to recapitulate the disease phenotype and are limited in scalability and functionality.
Innovation Solution
The development of protocols for directed differentiation of pluripotent stem cells, particularly human pluripotent stem cells, into functional endothelial cells and pericytes using defined media and timed growth factor addition, which can be cryopreserved and used in co-culture systems to model vascular diseases, including HHT, by capturing disease phenotypes and facilitating high-throughput screening for angiogenic or anti-angiogenic compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for producing endothelial cells and pericytes are used, then cell production is achieved, but the methods are inefficient and fail to recapitulate disease phenotypes
Solution Approach 1:
The patent applies parameter changes by modifying culture conditions including defined media composition, growth factor concentrations (VEGF, bFGF, TGFβ), and oxygen tension (2% O2) to optimize both cell production efficiency and disease phenotype recapitulation. These parameter adjustments enable simultaneous improvement of productivity and reliability in vascular cell generation from hPSCs
Solution Approach 2:
The patent implements preliminary action through pre-differentiation protocols that generate endothelial cell progenitors before final maturation. This staged approach allows optimization of each differentiation stage separately, improving overall efficiency while maintaining the ability to capture disease-specific phenotypes in the final cell population
2Productivity
If aggregation step is included in differentiation protocol, then differentiation efficiency may improve, but process complexity increases
Solution Approach 1:
The patent employs copying by using defined media formulations that replicate the signaling environment of in vivo vascular development. This chemical replication eliminates the need for complex aggregation steps while maintaining differentiation efficiency, as the defined growth factors and media composition mimic physiological conditions without requiring cell-cell contact or 3D structure formation
3Reliability
If primary endothelial cells from patients are used, then disease phenotypes can be studied, but cell expansion capability is limited
Solution Approach 1:
The patent applies universality by developing a platform where hPSCs can be differentiated into patient-specific endothelial cells that maintain disease phenotypes. This universal approach works across different disease types and patient samples, enabling both reliable disease modeling and scalable cell production through the renewable hPSC source
4Productivity
If more growth factors are added to differentiation media, then differentiation efficiency improves, but cost and media complexity increase
Solution Approach 1:
The patent optimizes growth factor parameters by determining minimal effective concentrations of VEGF, bFGF, and TGFβ required for each differentiation stage. This parameter optimization reduces media complexity and cost while maintaining high differentiation efficiency, as the defined protocol specifies exact concentrations and timing for each growth factor addition
Data Source
Figure 1A
Figure 1B
Figure 2A~2D
AI summary
The invention is concerned among others with means and methods for obtaining endothelial cells and to means and methods for in vitro cell culture comprising endothelial cells and pericytes and/or smooth muscle cells derived from said pericytes. The endothelial cells or the pericytes and/or smooth muscle cells, or both are preferably derived from in vitro differentiated pluripotent stem cells.